Gritstone bio Inc is a United States-based biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate.

Employees

231

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - OTC Markets Other stock markets 16:27:48 03/04/2025 BST			5-day change	1st Jan Change
- ^USD	-90.00%		-.--%	-

04/04/25	Gritstone bio, Inc. Emerged from Bankruptcy	CI
03/04/25	First Amended Reorganization Plan Approved for Gritstone bio, Inc.	CI

Capitalization	1.85M 1.59M 1.45M 1.39M 2.54M 177M 2.58M 17.43M 6.74M 84.09M 6.93M 6.78M 293M	P/E ratio 2022	-2.61x	P/E ratio 2023	-1.7x
Enterprise value	27.35M 23.53M 21.52M 20.53M 37.63M 2.62B 38.26M 258M 99.89M 1.25B 103M 100M 4.34B	EV / Sales 2022	7.62x	EV / Sales 2023	13.5x
Free-Float	98.27%	Yield 2022 *	-	Yield 2023	-

04/04/25	Gritstone bio, Inc. Emerged from Bankruptcy	CI
03/04/25	First Amended Reorganization Plan Approved for Gritstone bio, Inc.	CI
20/02/25	First Motion for Exclusivity Period Extension Approved For Gritstone bio, Inc.	CI
12/02/25	First Amended Disclosure Statement Approved for Gritstone bio, Inc.	CI
11/02/25	First Amended Disclosure Statement Filed by Gritstone bio, Inc.	CI
31/01/25	First Motion for Exclusivity Period Extension Filed by Gritstone bio, Inc.	CI
15/01/25	Reorganization Plan and Disclosure Statement Filed by Gritstone bio, Inc.	CI
03/01/25	Gritstone Bio, Inc. Announces CEO Changes	CI
03/01/25	Gritstone Bio, Inc. Announces Resignation of Executives	CI
29/12/24	Seattle Project Corp completed the acquisition of Substantially all of the assets of Gritstone bio, Inc. from Gritstone bio, Inc. (OTCPK:GRTS.Q).	CI
23/12/24	Motion for Asset Sale Approved for Gritstone bio, Inc.	CI
20/12/24	Motion for Asset Sale Approved for Gritstone bio, Inc.	CI
13/12/24	Notice of Successful Bidders Filed by Gritstone bio, Inc.	CI

01/10/24	B. Riley Downgrades Gritstone bio to Neutral From Buy, $1 Price Target; Shares Plummet	MT
01/10/24	HC Wainwright Downgrades Gritstone bio to Neutral From Buy, Adjusts Price Target to $0.50 From $4	MT
01/10/24	JMP Securities Downgrades Gritstone bio to Market Perform From Outperform	MT
24/05/24	B. Riley Cuts Price Target on Gritstone bio to $3 From $6, Keeps Buy Rating	MT
07/12/23	B. Riley Adjusts Gritstone bio's Price Target to $6 From $8, Keeps Buy Rating	MT

Gritstone bio, Inc. Share Price

Equities

GRTS

US39868T1051

Biotechnology & Medical Research

Valuation: Gritstone bio, Inc.

Latest news : Gritstone bio, Inc.

Analysts' recommendations: Gritstone bio, Inc.

Press Releases: Gritstone bio, Inc.

News in other languages: Gritstone bio, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Gritstone bio, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

13/12/24	Gritstone bio : Regulation FD Disclosure Form 8 K	PU
29/11/24	Gritstone bio : Regulation FD Presentation Form 8 K	PU
15/11/24	Gritstone bio : Bankruptcy Form 8 K	PU
11/11/24	Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update	AQ
10/10/24	Gritstone bio : Takes Action to Preserve Value and Strengthen Capital Structure Form 8 K	PU

26/07/23	Moderna/Merck inicia estudio de fase final de combinación de vacunas contra el cáncer de piel
16/03/21	ENFOQUE-Dinero y talento se mueven al sector del ARN mensajero tras éxito con COVID-19
19/01/21	MÄRKTE USA/Wall Street schließt freundlich mit Yellen-Rede
19/01/21	MÄRKTE USA/Wall Street freundlich mit Yellen und Banken-Zahlen

Manager	Title	Age	Since
Vassiliki Economides CEO	Chief Executive Officer	46	30/12/2024
Stacy Lea Proctor HRO	Human Resources Officer	-	-
James Cho AUD	Comptroller/Controller/Auditor	-	26/01/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GRITSTONE BIO, INC.	-90.00%	-.--%	-	-	147
ARGENX SE	-0.14%	+3.34%	+37.43%	+82.52%	50.1B
WUXI APPTEC CO., LTD.	+0.12%	-3.44%	+68.07%	+52.11%	45.82B
INSMED INCORPORATED	-5.60%	+7.69%	+60.22%	+488.04%	23.66B
BIONTECH SE	-2.65%	-4.86%	-3.47%	-14.84%	22.65B
WUXI BIOLOGICS (CAYMAN) INC.	+3.19%	+3.12%	+43.01%	-24.91%	17.8B
GENMAB A/S	-1.66%	+2.59%	+27.48%	-40.33%	16.08B
AKESO, INC.	-2.91%	-10.30%	+43.95%	+219.26%	14.14B
SUMMIT THERAPEUTICS INC.	-7.00%	-6.69%	-29.33%	+898.22%	13.09B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.41%	-2.37%	+35.93%	-	13B
Average	-10.62%	-2.00%	+31.48%	+207.51%	21.63B
Weighted average by Cap.	-1.35%	-1.31%	+38.15%	+154.93%

	2022	2023
Net sales	19.94M 17.16M 15.69M 14.97M 27.45M 1.91B 27.9M 188M 72.85M 908M 74.85M 73.25M 3.16B	16.34M 14.06M 12.86M 12.27M 22.49M 1.57B 22.86M 154M 59.7M 744M 61.34M 60.02M 2.59B
Net income	-120M -103M -94.17M -89.84M -165M -11.48B -167M -1.13B -437M -5.45B -449M -440M -18.99B	-138M -119M -109M -104M -191M -13.29B -194M -1.31B -506M -6.31B -520M -509M -21.97B
Net Debt	-136M -117M -107M -102M -187M -13.01B -190M -1.28B -495M -6.18B -509M -498M -21.52B	25.5M 21.94M 20.06M 19.14M 35.09M 2.45B 35.67M 241M 93.14M 1.16B 95.7M 93.65M 4.05B

3 years	0		3.33
5 years	0		14.42
10 years	0		35.2